A 12 Week, Multicenter, Open Label Evaluation of Caregiver Preference, Safety and Tolerability of Exelon® Patch (Rivastigmine Transdermal) in Patients With Alzheimer's Disease

PHASE4CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

April 30, 2010

Primary Completion Date

January 31, 2012

Study Completion Date

January 31, 2012

Conditions

Alzheimer's Disease

Interventions

DRUG

Rivastigmine transdermal

Trial Locations (5)

Novartis Investigative Site, Ashkelon

Novartis Investigational Site, Haifa

Novartis Investigative Site, Holon

Novartis Investigative Site, Ramat Gan

Novartis Investigative Site, Tel Aviv